RGNX News

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today!

Class Action Lawsuit Reminder from Pomerantz LLP for Shareholders of REGENXBIO Inc. – RGNX

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

RGNX EQUITY ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 Ready to Announce with Confidence?

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Gene Therapies in Ophthalmology Market Competitive Landscape Report 2026: Comprehensive Insights About 55+ Companies and 125+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Kyndryl Holdings, Inc. (KD), uniQure N.V. (QURE), and REGENXBIO Inc. (RGNX) Announced by Holzer & Holzer, LLC